Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jazz Pharmaceuticals is conducting a study titled ‘Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)’. The study aims to observe the effects of Epidyolex® on seizures in patients with LGS, DS, and TSC in Italy, highlighting its potential to improve patient outcomes in these challenging conditions.
The intervention being tested is Epidiolex 100 mg/mL Oral Solution, a drug intended to be used as an additional treatment for managing seizures in patients with the specified conditions. It is administered as per routine clinical practice.
This observational study follows a cohort model with a prospective time perspective. It involves real-world participants over a 52-week treatment period, focusing on gathering data on the drug’s effectiveness and safety in a naturalistic setting.
The study began on July 29, 2022, with an estimated completion date in August 2025. The most recent update was submitted on August 26, 2025, indicating ongoing recruitment and data collection.
For investors, the progress of this study could influence Jazz Pharmaceuticals’ stock performance, as positive outcomes may enhance the company’s market position in the epilepsy treatment sector. Competitors in the pharmaceutical industry are also advancing similar treatments, making this study’s results significant for maintaining a competitive edge.
The study is currently recruiting, with further details available on the ClinicalTrials portal.